Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 10/20 | 0.44 |
| ▸ | BACE1 | P56817 | 9/20 | 0.44 |
| ▸ | BACE2 | Q9Y5Z0 | 5/20 | 0.42 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.41 |
| ▸ | MLNR | O43193 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | CTSE | P14091 | 1/20 | 0.38 |
| ▸ | PGC | P20142 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862405 | 1.00 | CTSD (0.44) | CTSDBACE1BACE2SPPL2AMLNR | |
| SCHEMBL4877795 | 0.91 | CTSD (0.44) | CTSDBACE1BACE2SPPL2AMLNR | |
| SCHEMBL4877803 | 0.91 | CTSD (0.44) | CTSDBACE1BACE2SPPL2AMLNR | |
| SCHEMBL4870747 | 0.90 | CTSD (0.43) | CTSDBACE1BACE2SPPL2AMLNR | |
| SCHEMBL4870753 | 0.90 | CTSD (0.43) | CTSDBACE1BACE2SPPL2AMLNR | |
| SCHEMBL4872912 | 0.90 | MLNR (0.44) | CTSDSPPL2AMLNRABCB11LMNA | |
| SCHEMBL7430773 | 0.90 | MLNR (0.44) | CTSDSPPL2AMLNRABCB11LMNA | |
| SCHEMBL4872903 | 0.90 | MLNR (0.44) | CTSDSPPL2AMLNRABCB11LMNA | |
| SCHEMBL7430780 | 0.90 | MLNR (0.44) | CTSDSPPL2AMLNRABCB11LMNA | |
| SCHEMBL4873997 | 0.90 | CTSD (0.42) | CTSDBACE1BACE2SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| EP-1086076-B1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2004-12-22 | — | — | EP | disclosed |
| US-6613743-B2 | Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-25 | — | — | US | disclosed |
| EP-1086076-A1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065870-A2 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CTSD 93/4885BACE1 69/4885BACE2 36/4885 |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | CTSD 93/4885BACE1 69/4885BACE2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.